DelistingMay 22, 2026, 08:08 AM
GT Biopharma Gets Nasdaq Bid Price Compliance Extension to Nov 16
AI Summary
GT Biopharma, Inc. received an additional 180-calendar day extension from Nasdaq until November 16, 2026, to regain compliance with the minimum $1.00 bid price requirement. The company was initially notified of non-compliance on November 20, 2025, with an initial period ending May 19, 2026. Nasdaq granted the extension as GT Biopharma meets other listing requirements. The company intends to monitor its stock price and evaluate options to maintain its Nasdaq listing.
Key Highlights
- Received Nasdaq letter on May 20, 2026, granting a compliance extension.
- New deadline to regain minimum bid price compliance is November 16, 2026.
- Requires common stock to close at $1.00 or more for 10 consecutive business days.
- Initial non-compliance notice received on November 20, 2025.
- Initial compliance period ended on May 19, 2026.
- Company meets all other Nasdaq Capital Market listing requirements.
- GT Biopharma will monitor stock price and assess options to regain compliance.
Price Impact
More from GTBP